share_log

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Plus 治療藥物宣布首位用於治療復發性膠質母細胞瘤的錸(186Re)obisbemeda 的 2B 期試驗中的患者
Benzinga Real-time News ·  2023/01/18 07:02

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Plus 治療藥物宣布首位用於治療復發性膠質母細胞瘤的錸(186Re)obisbemeda 的 2B 期試驗中的患者

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論